Publications

Borgini M, Huang QN, Chen PP, Geib SJ, Houk KN, Wipf P. Rhodium(I)-Catalyzed Annulation of Bicyclo[1.1.0]butyl-Substituted Dihydroquinolines and Dihydropyridines. J Am Chem Soc. 2024-06-05; doi: 10.1021/jacs.4c04081. PubMed PMID: 38767459; PMCID: PMC11157536.

Chen Y, Chen CY, Huang H, Luo Z, Mu Y, Li S, Li S. Knocking down of Xkr8 enhances chemotherapy efficacy through modulating tumor immune microenvironment. J Control Release. 2024-06-01; doi: 10.1016/j.jconrel.2024.04.041. PubMed PMID: 38685385; PMCID: PMC11186464.

Hertz DL, Joerger M, Bang YJ, Mathijssen RH, Zhou C, Zhang L, Gandara D, Stahl M, Monk BJ, Jaehde U, Beumer JH. Paclitaxel therapeutic drug monitoring - International association of therapeutic drug monitoring and clinical toxicology recommendations. Eur J Cancer. 2024-05-01;202114024. doi: 10.1016/j.ejca.2024.114024. PubMed PMID: 38513383; PMCID: PMC11053297.

Butrovich MA, Qin J, Xue X, Ivy SP, Nolin TD, Beumer JH. Impact of the 2021 CKD-EPI equation on anticancer pharmacotherapy in black and non-black cancer patients. Cancer Lett. 2024-04-01;216679. doi: 10.1016/j.canlet.2024.216679. PubMed PMID: 38307411; PMCID: PMC10939791.

Chen Y, Chen CY, Huang H, Luo Z, Mu Y, Li S, Li S. Knocking down of Xkr8 enhances chemotherapy efficacy through modulating tumor immune microenvironment. J Control Release. 2024-03-10; doi: 10.1016/j.jconrel.2024.03.011. PubMed PMID: 38471639.

Chao Y, Chen Y, Zheng W, Demanelis K, Liu Y, Connelly JA, Wang H, Li S, Wang QJ. Synthetic lethal combination of CHK1 and WEE1 inhibition for treatment of castration-resistant prostate cancer. Oncogene. 2024-03-01; doi: 10.1038/s41388-024-02939-z. PubMed PMID: 38273024.

Beumer JH, Salamone SJ. Project Confirm: Accelerated Drug Approvals for CML-Letter. Clin Cancer Res. 2024-01-05;30(1):235-236. doi: 10.1158/1078-0432.CCR-23-2630. PubMed PMID: 38178775; PMCID: PMC10783536.

Luo Z, Huang Y, Batra N, Chen Y, Huang H, Wang Y, Zhang Z, Li S, Chen CY, Wang Z, Sun J, Wang QJ, Yang D, Lu B, Conway JF, Li LY, Yu AM, Li S. Inhibition of iRhom1 by CD44-targeting nanocarrier for improved cancer immunochemotherapy. Nat Commun. 2024-01-04;15(1):255. doi: 10.1038/s41467-023-44572-6. PubMed PMID: 38177179; PMCID: PMC10766965.

Chen Y, Huang Y, Li Q, Luo Z, Zhang Z, Huang H, Sun J, Zhang L, Sun R, Bain DJ, Conway JF, Lu B, Li S. Targeting Xkr8 via nanoparticle-mediated in situ co-delivery of siRNA and chemotherapy drugs for cancer immunochemotherapy. Nat Nanotechnol. 2023-02-01;18(2):193-204. doi: 10.1038/s41565-022-01266-2. PubMed PMID: 36424448; PMCID: PMC9974593.

Zhang Y, Li J, Huang Y, Chen Y, Luo Z, Huang H, West RE 3rd, Nolin TD, Wang Z, Li S. Improved antitumor activity against prostate cancer via synergistic targeting of Myc and GFAT-1. Theranostics. 2023-01-01;13(2):578-595. doi: 10.7150/thno.76614. PubMed PMID: 36632215; PMCID: PMC9830436.

Beumer JH, Chu E, Salamone SJ. All Optimal Dosing Roads Lead to Therapeutic Drug Monitoring-Why Take the Slow Lane. JAMA Oncol. 2022-12-01;8(12):1733-1735. doi: 10.1001/jamaoncol.2022.4452. PubMed PMID: 36264552; PMCID: PMC9772116.

Moharil P, Wan Z, Pardeshi A, Li J, Huang H, Luo Z, Rathod S, Zhang Z, Chen Y, Zhang B, Fernandez CA, Sun J, Li S. Engineering a folic acid-decorated ultrasmall gemcitabine nanocarrier for breast cancer therapy: Dual targeting of tumor cells and tumor-associated macrophages. Acta Pharm Sin B. 2022-03-01;12(3):1148-1162. doi: 10.1016/j.apsb.2021.09.024. PubMed PMID: 35530140; PMCID: PMC9072252.

Wan Z, Sun R, Liu YW, Li S, Sun J, Li J, Zhu J, Moharil P, Zhang B, Ren P, Ren G, Zhang M, Ma X, Dai S, Yang D, Lu B, Li S. Targeting metabotropic glutamate receptor 4 for cancer immunotherapy. Sci Adv. 2021-12-10;7(50):eabj4226. doi: 10.1126/sciadv.abj4226. PubMed PMID: 34890233; PMCID: PMC8664261.

Namburi S, Broxmeyer HE, Hong CS, Whiteside TL, Boyiadzis M. DPP4(+) exosomes in AML patients' plasma suppress proliferation of hematopoietic progenitor cells. Leukemia. 2021-07-01;35(7):1925-1932. doi: 10.1038/s41375-020-01047-7. PubMed PMID: 33139859; PMCID: PMC10165724.

Colen RR, Rolfo C, Ak M, Ayoub M, Ahmed S, Elshafeey N, Mamindla P, Zinn PO, Ng C, Vikram R, Bakas S, Peterson CB, Rodon Ahnert J, Subbiah V, Karp DD, Stephen B, Hajjar J, Naing A. Author response to Cunha et al. J Immunother Cancer. 2021-07-01;9(7): doi: 10.1136/jitc-2021-003299. PubMed PMID: 34315823; PMCID: PMC8317086.

Lontos K, Yabes JG, Farah RJ, Boyiadzis M. Impact of upfront chemotherapy on overall survival in isolated myeloid sarcoma. Leukemia. 2021-04-01;35(4):1193-1196. doi: 10.1038/s41375-020-01017-z. PubMed PMID: 32814841.

Colen RR, Rolfo C, Ak M, Ayoub M, Ahmed S, Elshafeey N, Mamindla P, Zinn PO, Ng C, Vikram R, Bakas S, Peterson CB, Rodon Ahnert J, Subbiah V, Karp DD, Stephen B, Hajjar J, Naing A. Radiomics analysis for predicting pembrolizumab response in patients with advanced rare cancers. J Immunother Cancer. 2021-04-01;9(4): doi: 10.1136/jitc-2020-001752. PubMed PMID: 33849924; PMCID: PMC8051405.

Huang H, Huang Y, Chen Y, Luo Z, Zhang Z, Sun R, Wan Z, Sun J, Lu B, Zhang L, Hu J, Li S. A novel immunochemotherapy based on targeting of cyclooxygenase and induction of immunogenic cell death. Biomaterials. 2021-03-01;270120708. doi: 10.1016/j.biomaterials.2021.120708. PubMed PMID: 33578254; PMCID: PMC7910750.

Sun J, Wan Z, Xu J, Luo Z, Ren P, Zhang B, Diao D, Huang Y, Li S. Tumor size-dependent abscopal effect of polydopamine-coated all-in-one nanoparticles for immunochemo-photothermal therapy of early- and late-stage metastatic cancer. Biomaterials. 2021-02-01;269120629. doi: 10.1016/j.biomaterials.2020.120629. PubMed PMID: 33387938; PMCID: PMC8466812.

Hasan MN, Luo L, Ding D, Song S, Bhuiyan MIH, Liu R, Foley LM, Guan X, Kohanbash G, Hitchens TK, Castro MG, Zhang Z, Sun D. Blocking NHE1 stimulates glioma tumor immunity by restoring OXPHOS function of myeloid cells. Theranostics. 2021-01-01;11(3):1295-1309. doi: 10.7150/thno.50150. PubMed PMID: 33391535; PMCID: PMC7738877.

Boyiadzis MM, Aksentijevich I, Arber DA, Barrett J, Brentjens RJ, Brufsky J, Cortes J, De Lima M, Forman SJ, Fuchs EJ, Fukas LJ, Gore SD, Litzow MR, Miller JS, Pagel JM, Waller EK, Tallman MS. The Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of acute leukemia. J Immunother Cancer. 2020-10-01;8(2): doi: 10.1136/jitc-2020-000810. PubMed PMID: 33077513; PMCID: PMC7574947.

Ma W, Sun J, Xu J, Luo Z, Diao D, Zhang Z, Oberly PJ, Minnigh MB, Xie W, Poloyac SM, Huang Y, Li S. Sensitizing Triple Negative Breast Cancer to Tamoxifen Chemotherapy via a Redox-Responsive Vorinostat-containing Polymeric Prodrug Nanocarrier. Theranostics. 2020-01-20;10(6):2463-2478. doi: 10.7150/thno.38973. PubMed PMID: 32194813; PMCID: PMC7052901.

Sun J, Chen Y, Xu J, Song X, Wan Z, Du Y, Ma W, Li X, Zhang L, Li S. High Loading of Hydrophobic and Hydrophilic Agents via Small Immunostimulatory Carrier for Enhanced Tumor Penetration and Combinational Therapy. Theranostics. 2020-01-01;10(3):1136-1150. doi: 10.7150/thno.38287. PubMed PMID: 31938056; PMCID: PMC6956803.

Elshafeey N, Kotrotsou A, Hassan A, Elshafei N, Hassan I, Ahmed S, Abrol S, Agarwal A, El Salek K, Bergamaschi S, Acharya J, Moron FE, Law M, Fuller GN, Huse JT, Zinn PO, Colen RR. Multicenter study demonstrates radiomic features derived from magnetic resonance perfusion images identify pseudoprogression in glioblastoma. Nat Commun. 2019-07-18;10(1):3170. doi: 10.1038/s41467-019-11007-0. PubMed PMID: 31320621; PMCID: PMC6639324.

Xu J, Sun J, Ho PY, Luo Z, Ma W, Zhao W, Rathod SB, Fernandez CA, Venkataramanan R, Xie W, Yu AM, Li S. Creatine based polymer for codelivery of bioengineered MicroRNA and chemodrugs against breast cancer lung metastasis. Biomaterials. 2019-07-01;21025-40. doi: 10.1016/j.biomaterials.2019.04.025. PubMed PMID: 31054369; PMCID: PMC6538300.

Boyiadzis MM, Dhodapkar MV, Brentjens RJ, Kochenderfer JN, Neelapu SS, Maus MV, Porter DL, Maloney DG, Grupp SA, Mackall CL, June CH, Bishop MR. Chimeric antigen receptor (CAR) T therapies for the treatment of hematologic malignancies: clinical perspective and significance. J Immunother Cancer. 2018-12-04;6(1):137. doi: 10.1186/s40425-018-0460-5. PubMed PMID: 30514386; PMCID: PMC6278156.

Xu J, Zhao W, Sun J, Huang Y, Wang P, Venkataramanan R, Yang D, Ma X, Rana A, Li S. Novel glucosylceramide synthase inhibitor based prodrug copolymer micelles for delivery of anticancer agents. J Control Release. 2018-10-28;288212-226. doi: 10.1016/j.jconrel.2018.09.011. PubMed PMID: 30223045; PMCID: PMC6177216.

Boyiadzis MM, Kirkwood JM, Marshall JL, Pritchard CC, Azad NS, Gulley JL. Significance and implications of FDA approval of pembrolizumab for biomarker-defined disease. J Immunother Cancer. 2018-05-14;6(1):35. doi: 10.1186/s40425-018-0342-x. PubMed PMID: 29754585; PMCID: PMC5950135.

Lee DM, Duensing A. What's the FOX Got to Do with the KITten? Regulating the Lineage-Specific Transcriptional Landscape in GIST. Cancer Discov. 2018-02-01;8(2):146-149. doi: 10.1158/2159-8290.CD-17-1370. PubMed PMID: 29431674.

Sun J, Liu Y, Chen Y, Zhao W, Zhai Q, Rathod S, Huang Y, Tang S, Kwon YT, Fernandez C, Venkataramanan R, Li S. Doxorubicin delivered by a redox-responsive dasatinib-containing polymeric prodrug carrier for combination therapy. J Control Release. 2017-07-28;25843-55. doi: 10.1016/j.jconrel.2017.05.006. PubMed PMID: 28501705; PMCID: PMC5525542.

Yin Y, Sun G, Li E, Kiselyov K, Sun D. ER stress and impaired autophagy flux in neuronal degeneration and brain injury. Ageing Res Rev. 2017-03-01;343-14. doi: 10.1016/j.arr.2016.08.008. PubMed PMID: 27594375; PMCID: PMC5250579.

Boyiadzis M, Bishop MR, Abonour R, Anderson KC, Ansell SM, Avigan D, Barbarotta L, Barrett AJ, Van Besien K, Bergsagel PL, Borrello I, Brody J, Brufsky J, Cairo M, Chari A, Cohen A, Cortes J, Forman SJ, Friedberg JW, Fuchs EJ, Gore SD, Jagannath S, Kahl BS, Kline J, Kochenderfer JN, Kwak LW, Levy R, de Lima M, Litzow MR, Mahindra A, Miller J, Munshi NC, Orlowski RZ, Pagel JM, Porter DL, Russell SJ, Schwartz K, Shipp MA, Siegel D, Stone RM, Tallman MS, Timmerman JM, Van Rhee F, Waller EK, Welsh A, Werner M, Wiernik PH, Dhodapkar MV. The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of hematologic malignancies: multiple myeloma, lymphoma, and acute leukemia. J Immunother Cancer. 2016-12-20;490. doi: 10.1186/s40425-016-0188-z. PubMed PMID: 28018601; PMCID: PMC5168808.

Chen Y, Xia R, Huang Y, Zhao W, Li J, Zhang X, Wang P, Venkataramanan R, Fan J, Xie W, Ma X, Lu B, Li S. An immunostimulatory dual-functional nanocarrier that improves cancer immunochemotherapy. Nat Commun. 2016-11-07;713443. doi: 10.1038/ncomms13443. PubMed PMID: 27819653; PMCID: PMC5103075.

Li J, Li S. Reply to: "miR-122 expression is not regulated during activation of hepatic stellate cells". J Hepatol. 2016-10-01;65(4):868. doi: 10.1016/j.jhep.2016.06.020. PubMed PMID: 27388922.

Beumer JH, Tawbi H, Ivy SP. Reply to V. Launay-Vacher, T. Shimokata et al, and C. Porta et al. J Clin Oncol. 2016-07-10;34(20):2430-1. doi: 10.1200/JCO.2016.67.2790. PubMed PMID: 27185845.

Milligan JA, Wipf P. Click chemistry: Straining to react. Nat Chem. 2016-04-01;8(4):296-7. doi: 10.1038/nchem.2485. PubMed PMID: 27001724.

Beumer JH, Ding F, Tawbi H, Lin Y, Viluh D, Chatterjee I, Rinker M, Chow SL, Ivy SP. Effect of Renal Dysfunction on Toxicity in Three Decades of Cancer Therapy Evaluation Program-Sponsored Single-Agent Phase I Studies. J Clin Oncol. 2016-01-10;34(2):110-6. doi: 10.1200/JCO.2014.59.7302. PubMed PMID: 26392101; PMCID: PMC4980565.

Zhang P, Li J, Ghazwani M, Zhao W, Huang Y, Zhang X, Venkataramanan R, Li S. Effective co-delivery of doxorubicin and dasatinib using a PEG-Fmoc nanocarrier for combination cancer chemotherapy. Biomaterials. 2015-10-01;67104-14. doi: 10.1016/j.biomaterials.2015.07.027. PubMed PMID: 26210177; PMCID: PMC4550547.

Ivy SP, Beumer JH. Ovarian Cancer Survival and Chemotherapy Dosing, Body Mass Index, and Body Surface Area : Are We There Yet? JAMA Oncol. 2015-09-01;1(6):732-3. doi: 10.1001/jamaoncol.2015.1926. PubMed PMID: 26181495; PMCID: PMC4696392.

Lu J, Liu C, Wang P, Ghazwani M, Xu J, Huang Y, Ma X, Zhang P, Li S. The self-assembling camptothecin-tocopherol prodrug: An effective approach for formulating camptothecin. Biomaterials. 2015-09-01;62176-87. doi: 10.1016/j.biomaterials.2015.05.046. PubMed PMID: 26057133; PMCID: PMC4470812.

Boyiadzis M, Arora M, Klein JP, Hassebroek A, Hemmer M, Urbano-Ispizua A, Antin JH, Bolwell BJ, Cahn JY, Cairo MS, Cutler CS, Flowers ME, Gale RP, Herzig R, Isola LM, Jacobsohn DA, Jagasia MH, Klumpp TR, Lee SJ, Petersdorf EW, Santarone S, Spellman SR, Schouten HC, Verdonck LF, Wingard JR, Weisdorf DJ, Horowitz MM, Pavletic SZ. Impact of Chronic Graft-versus-Host Disease on Late Relapse and Survival on 7,489 Patients after Myeloablative Allogeneic Hematopoietic Cell Transplantation for Leukemia. Clin Cancer Res. 2015-05-01;21(9):2020-8. doi: 10.1158/1078-0432.CCR-14-0586. PubMed PMID: 25348512; PMCID: PMC4411210.

Duensing A. Targeting ETV1 in gastrointestinal stromal tumors: tripping the circuit breaker in GIST? Cancer Discov. 2015-03-01;5(3):231-3. doi: 10.1158/2159-8290.CD-15-0116. PubMed PMID: 25749973.

Lu J, Zhao W, Liu H, Marquez R, Huang Y, Zhang Y, Li J, Xie W, Venkataramanan R, Xu L, Li S. An improved D-α-tocopherol-based nanocarrier for targeted delivery of doxorubicin with reversal of multidrug resistance. J Control Release. 2014-12-28;196272-86. doi: 10.1016/j.jconrel.2014.10.016. PubMed PMID: 25456831; PMCID: PMC4267990.

Zhang P, Huang Y, Liu H, Marquez RT, Lu J, Zhao W, Zhang X, Gao X, Li J, Venkataramanan R, Xu L, Li S. A PEG-Fmoc conjugate as a nanocarrier for paclitaxel. Biomaterials. 2014-08-01;35(25):7146-56. doi: 10.1016/j.biomaterials.2014.04.108. PubMed PMID: 24856103; PMCID: PMC4102141.